North America Recombinant Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America Recombinant Albumin Market size is expected to reach US$ 356,576.1 Million by 2031 from US$ 188,193.7 Million in 2024. The market is estimated to record a CAGR of 9.6% from 2025 to 2031.

Executive Summary and North America Recombinant Albumin Market Analysis:

The recombinant albumin market in North America is experiencing significant growth driven by increasing clinical demand for safer and more consistent plasma protein products. According to the U.S. FDA, the prevalence of conditions requiring albumin therapy such as liver cirrhosis, burns, and shock has increased significantly. The CDC reported an estimated 40,000 new cases of liver cirrhosis annually in the US as of 2023. The growing adoption of recombinant albumin is also supported by advancements in biotechnology, leading to the development of safer, scalable, and ethically sustainable products. Notably, in 2022, the FDA approved new recombinant albumin formulations that reduce the risk of pathogen transmission compared to plasma-derived options, aligning with increasing safety concerns. Ongoing research and product innovations, such as the launch of recombinant albumin-based therapies for critical care and oncology, and fuel market expansion. Government initiatives, including funding for biotechnology research and stricter regulations on plasma-derived products, encourage the shift toward recombinant alternatives. The COVID-19 pandemic underscored the importance of reliable biopharmaceuticals, further accelerating market growth. As of 2024, regulatory agencies continued to endorse recombinant albumin as a safer option for albumin therapies.

North America Recombinant Albumin Market: Strategic Insights

North America Recombinant Albumin Market Segmentation Analysis:

• By Source, the North America Recombinant Albumin Market is segmented into Human Recombinant Albumin, Bovine Recombinant Albumin, and Other Sources. The Human Recombinant Albumin segment dominated the market in 2024.
• By Application, the North America Recombinant Albumin Market is segmented into Excipient in Biotherapeutics and Vaccines, Cell Culture, Drug Delivery, Diagnostics, and Other Applications. The Excipient in Biotherapeutics and Vaccines segment dominated the market in 2024.
• By End User, the North America Recombinant Albumin Market is segmented into Pharmaceutical and Biotechnology Companies, Research Institutes, Hospitals and Diagnostic Laboratories, and Others End Users. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

North America Recombinant Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The North America Recombinant Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Recombinant Albumin Market Outlook

The growing cases of liver ailments and other related health concerns have become one of the key factors behind the rising global recombinant albumin market. The development of long-term liver problems such as chronic hepatitis B and hepatitis C infections has been among the most common causes behind cirrhosis, liver failure, and liver cancer, resulting in hypoalbuminemia and the requirement for albumin treatments. Statistics show that viral hepatitis infections cause nearly 1.3 million people around the world to die each year due to these infections that remain one of the greatest health burdens on a global scale (World Health Organization, April 2024).

 In the US, data from the CDC indicate a 7% rise in hospitalizations for liver-related conditions from 2022 to 2023, highlighting the growing clinical need for albumin-based therapies. As liver dysfunction often results in hypoalbuminemia, clinicians increasingly rely on albumin products to manage volume expansion, correct plasma protein deficits, and improve patient outcomes. Recent advancements, such as the approval of recombinant human albumin by the FDA in 2023, provide safer and more scalable alternatives to plasma-derived products.

North America Recombinant Albumin Market Country Insights

By country, the North America Recombinant Albumin Market is segmented into the United States, Canada, and Mexico. The United States held the largest share in 2024.

The US witnesses a demand for safer biologic inputs, rising prevalence of liver disease, and evolving regulatory expectations. A recent study found the prevalence of cirrhosis to be 2.6% of the US adult population. Individuals with liver cirrhosis often develop hypoalbuminemia and require albumin administration. The Food and Drug Administration (FDA) issued a draft guidance in April 2024 titled "Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products." In this draft, the agency highlighted concerns over the use of human- or animal-derived materials such as albumin and feeds in advanced therapies and encouraged manufacturers to justify alternatives. This regulatory momentum places recombinant human serum albumin (rHSA) and other non-plasma-derived albumin products in a favorable position as safer, defined alternatives.

Advancements in cell-culture, gene, and cell therapies are accelerating in the US. These modalities rely on defined, animal-free excipients and manufacturing workflows, which makes recombinant albumin a preferred component for media, stabilization, and therapeutic delivery systems. Thus, the regulatory push toward non-animal materials, the high underlying disease-driven demand for albumin therapies, and the growth of biologics manufacturing underpin the market growth.

North America Recombinant Albumin Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc, CSL Ltd, Merck KGaA, Sartorius AG, Akron Biotech, HiMedia Laboratories Pvt Ltd, InVitria, Medxbio Pte Ltd, Lazuline Biotech Private Limited, and Cyagen Biosciences.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Recombinant Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise